GlassScriptPhysician profile
Thomas J Loss
NPI 1063973980
$1,409.37
in general payments reported to CMS, 2019-2025
13 companies · $857 in 2025
The $857 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $133 · 2024: $420 · 2025: $857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $900 · Food and Beverage: $509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $900.32 |
| Food and Beverage | $509.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $255.20 | 2024-2025 | Jakafi, Niktimvo |
| Lilly USA, LLC | $244.78 | 2025 | Verzenio, Jaypirca |
| Alexion Pharmaceuticals, INC. | $184.99 | 2025 | Soliris |
| Exelixis INC. | $178.00 | 2023-2024 | |
| Ipsen Biopharmaceuticals, INC | $166.93 | 2024-2025 | Onivyde |
| Sobi, INC | $145.39 | 2024-2025 | |
| Beigene USA, INC. | $50.07 | 2024 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $39.00 | 2024 | Calquence, Tagrisso |
| Novartis Pharmaceuticals Corporation | $36.78 | 2025 | |
| Blueprint Medicines Corporation | $31.87 | 2023 | Ayvakit |
| Stemline Therapeutics INC. | $30.91 | 2025 | Orserdu |
| Genzyme Corporation | $29.81 | 2024 | |
| Janssen Scientific Affairs, LLC | $15.64 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Loss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.